The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus

Abstract

We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodiesin patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodiesas compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.

Keywords

autoantibodies PAI-1 SLE

Get full access to this article

View all access options for this article.

References

Frampton G , Moriya S , Pearson JD et al. Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen . Rheumatology 2000; 39: 1114-1120 .

Booth NA. Fibrinolysis and thrombosis . Baillieres Clin Haematol 1999; 12: 423-433 .

Rougier J-P , Guia S , Hagege J , Nguyen G , Ronco PM. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-B1 . Kidney Int 1998; 54: 87-98 .

Loskutoff DJ , Curriden SA , Hu G , Deng G. Regulation of cell adhesion by PAI-1 . APMIS 1999; 107: 54-61 .

Noel A , Bajou K , Masson V et al. Regulation of cancer invasion and vascularisation by plasminogen activator inhibitor-1 . Fibrin Proteo 1999; 13: 220-225 .

Isogai C , Laug WE , Shimada H et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin . Cancer Res 2001; 61: 5587-5594 .

Cai W , Vosschulte R , Afsah-Hedjri A et al. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis . J Mol Cell Cardiol 2000; 32: 997-1011 .

Hay EM , Bacon PA , Gordon C. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . Q J Med 1993; 86: 44-58 .

Sancho E , Tonge DW , Hockney RC , Booth NA. Purification and characterisation of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli . Eur J Biochem 1994; 224: 125-134 .

10.

Frampton G , Perry GJ , Cameron JS. Anti-endothelial cell antibodies in renal diseases and renal transplantation, In: Cervera C , Khamashta MA , Hughes GRV (eds). Antibodies to endothelial cells and vascular damage. CRC Press: Boca Ratan, FL , 1994, pp 135-163.

11.

Carvalho D , Savage COS , Black CM , Pearson JD. IgG autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines . J Clin Invest 1996; 97: 111-112 .

12.

Patel A , Testoni C , Borghi MO , Graham AM , Meroni PL , Lindsey N. Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient bind and activates human endothelium in vitro . Intern Immunol 2001; 13: 349-335 .

13.

Meroni PL , Raschi E , Camera M , Testoni C , Nicoletti F , Tincani A , Khamashta MA , Balestrieri G , Tremoli E , Hess DC Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome . J Autoimmun 2000; 15: 237-240 .

14.

Sun KH , Tang SJ , Lin ML , Wang YS , Sun GH , Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture . Rheumatology 2001; 40: 750-756 .

15.

Frijns CJ , Derksen RH , De Groot PG , Algra A , Fijnheer, R. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus . Clin Exp Immunol 2001; 125: 149-154 .

16.

Shikata K , Makino H , Morioka S et al. Distribution of extracellular matrix receptors in various forms of glomerulonephritis . Am J Kid Dis 1995; 25: 680-688 .

17.

Afek A , Shoenfeld Y , Manor R et al. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome . Lupus 1999; 8: 502-507 .

18.

Byron MA , Allington MJ , Chapel HM , Mowat AG , Cederholm-Williams SA. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus . Ann Rheum Dis 1987; 46: 741-745 .